II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive, electrotherapeutic technologies, today announced financial results for its fiscal first quarter ended June 30, 2007. For the fiscal first quarter ended June 30, 2007, total revenue grew 112% to $460,999 from $217,419 for the quarter ended June 30, 2006. Revenues were primarily driven by the sale of the Company�s products to distributors and into medical facilities, and through our direct sales force into rental programs in the wound care market. Unit sales increased to $286,400 in the quarter, up 1677% from $16,115 in the first quarter of fiscal 2007. Rental revenue was $158,974 in the first quarter of fiscal 2008 compared to rental revenue was $201,304 for the same period of fiscal 2007. The Company also recorded licensing fee revenue of $15,625 in the fiscal first quarter related to the initial milestone payment received from Allergan and amortized over the initial term of our agreement with Allergan. The Company had a net loss of $1,412,608, or $0.15 per share, for the fiscal first quarter compared to a net loss of $1,877,958, or $0.40 per share, for the year ago period, which included $853,666 of interest and finance costs that did not impact the current quarter. On June 30, 2007, Ivivi Technologies had cash and cash equivalents of approximately $7.0 million, no outstanding long term debt and 9,596,908 common shares outstanding. �We remain committed to our strategy to demonstrate the efficacy and broad potential of our proprietary PEMF technology while utilizing partners for marketing and selling activities,� commented Andre� A. DiMino, Vice Chairman and Co-Chief Executive Officer. �The August 2007 journal Plastic and Reconstructive Surgery provided additional evidence that our technology can increase tensile strength using a standard wound model in animals. While this study demonstrated the ability of our non-invasive technology to help improve patient outcomes by strengthening wounds at an earlier stage in the recovery period, 59% in 21 days, it also demonstrated our ability to fine-tune the configuration of PEMF signals to help achieve a more precise signal for specific indications, which we hope will have positive implications to additional target markets.� �Beyond the aesthetic and bariatric surgery markets, where we have partnered with Allergan, we are in discussions with potential partners for markets including wound care and others and have, as previously announced, retained Jefferies & Company, Inc. as our financial advisor to provide assistance pursuing strategic partners with marketing and distribution channels for our products as well as advise us on financings and business strategy,� added Mr. DiMino. David Saloff, President and Co-Chief Executive Officer added, �Partnerships remain key to the acceleration we are hoping to achieve in sales as we move through fiscal 2008 and beyond. Allergan, our worldwide distribution partner in the aesthetic and bariatric surgery markets, is continuing with their premarketing launch activities. A great deal has been accomplished over the last several months including final product design and packaging, as well as the development of marketing and sales force training materials. The product launch is anticipated by our fiscal year end. We believe the launch will serve to expand the knowledge base for our technology and provide added validation of its efficacy. We also remain on track to file a 510(k) application by calendar year end for both a prescription and over-the-counter pain relief product as a non-pharmacologic alternative to pain relievers such as non-steroidal anti-inflammatory drugs for inflammatory conditions.� Management will discuss the Company's results for its fiscal first quarter ended June 30, 2007, during a conference call scheduled for today, Tuesday, August 14, 2007 at 4:30 pm ET. Shareholders and other interested parties may participate in the conference call by dialing (877) 407-0782 approximately 5 to 10 minutes before the beginning of the call. International callers should dial (201) 689-8567. If you are unable to participate, a replay of the call will be available until midnight on August 28, 2007 by dialing (877) 660-6853 and using pass code # 286 and conference ID # 251433. International callers should dial (201) 612-7415 and use the pass codes listed above. The call will also be broadcast live on the Internet at www.InvestorCalendar.com and on the Investor Relations section of the Company�s website www.ivivitechnologies.com. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including those related to our cardiac study at the Cleveland Clinic, strategic partnerships and future sales. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s Form 10-KSB for the fiscal year ended March 31, 2007. The Company assumes no obligation to update the information contained in this press release. IVIVI TECHNOLOGIES, INC. Statements of Operations � Three Months Ended June 30, (unaudited) 2007 2006 Revenues: Sales $ 286,400 $ 16,115 Rentals 158,974 201,304 Licensing � 15,625 � � -- � � 460,999 � � 217,419 � � Expenses: Cost of goods sold 71,597 14,134 Cost of rental revenue 15,442 27,573 Depreciation and amortization 16,278 2,436 Research and development 358,171 269,729 Sales and marketing 400,274 220,493 General and administrative 761,697 466,643 Share based compensation � 331,533 � � 218,413 � Total operating expenses � 1,954,992 � � 1,219,421 � Loss from operations (1,493,993 ) (1,002,002 ) � Change in fair value of warrant and registration rights liabilities -- (25,827 ) Interest income 81,385 3,537 Interest and finance costs � -- � � (853,666 ) � Loss before provision for income taxes (1,412,608 ) (1,877,958 ) Income taxes � -- � � -- � Net loss $ (1,412,608 ) $ (1,877,958 ) Net loss per share, basic and diluted $ (0.15 ) $ (0.40 ) Weighted average shares outstanding � 9,580,642 � � 4,745,000 � IVIVI TECHNOLOGIES, INC. Balance Sheet � June 30, 2007 March 31, 2007 (unaudited) (audited) Current assets Cash and cash equivalents $ 6,996,348 $ 8,310,697 Accounts receivable, net 336,357 224,349 Inventory finished goods 189,877 236,735 Prepaid expenses � 65,137 � � 154,730 � Total current assets 7,587,719 8,926,511 � Property and equipment, net 133,197 46,040 Equipment in use and under rental, net 76,036 60,096 Intangible assets, net � 344,581 � � 270,826 � Total assets $ 8,141,533 � $ 9,303,473 � � Current liabilities: Accounts payable and accrued expenses 910,276 $ 1,005,975 Advances payable � affiliates � 35,285 � � 36,657 � Total current liabilities 945,561 1,042,632 � Deferred revenue � 458,333 � � 473,958 � Total liabilities 1,403,894 1,516,590 � Stockholders� equity: Common stock 20,953,985 20,922,154 Additional paid-in capital 10,908,644 10,577,111 Accumulated deficit � (25,124,990 ) � (23,712,382 ) Total stockholders� equity � 6,737,639 � � 7,786,883 � � Total liabilities and stockholders� equity $ 8,141,533 � $ 9,303,473 �